The novel SubQperior tumor models overcome common challenges of subcutaneous tumor models based on improved tumor cell implantation technique. SubQperior efficacy studies provide outstanding statistical value due to homogenous tumor growth and absence of ulceration issues. In this webinar, we present how SubQperior syngeneic models are used at Reaction Biology to advance immune-oncology drug development programs to create efficacious immunotherapies. All oncology program leaders are welcome to take part in the webinar.
Click here for additional information and registration details.
Related Content
Evidence Matters 2022
Evidence Matters is a virtual one-day summit that brings the literature review community together from different industries to learn, engage, and solve ever-pressing evidence-based research challenges.
Achieving Consensus When Everyone is an Expert, but No One Agrees
Join experts from PHAR, Novartis, and Bausch Health for a discussion around the Delphi panels and how the results are used.
Accelerating the Generation of Payer Insights and Evidence Across the Product Lifecycle to Achieve Optimal Access
Experts will present opportunities for using agile platforms and fit-for-purpose engagement models that can drive an iterative approach to obtaining payer insights and developing impactful evidence generation strategies.